https://news.inve.money/vertex-s-new-spending-absorbed-most-of-its-third-quarter-revenue-growthInveen2026-11-05T23:40:50.488841+00:00Vertex's new spending absorbed most of its third-quarter revenue growthhttps://news.inve.money/arm-s-royalties-grew-8-as-a-licence-surge-carried-its-quarterInveen2026-11-05T23:38:55.974534+00:00Arm's royalties grew 8% as a licence surge carried its quarterhttps://news.inve.money/qualcomm-s-new-businesses-arrive-on-time-but-its-margin-repair-isInveen2026-11-05T23:38:52.262731+00:00Qualcomm's new businesses arrive on time, but its margin repair is dated to late fiscal 2027https://news.inve.money/beone-lifts-its-profit-guidance-again-but-the-range-implies-a-weakerInveen2026-11-05T23:13:14.993490+00:00BeOne lifts its profit guidance again, but the range implies a weaker fourth quarterhttps://news.inve.money/in/lic-s-value-growth-now-rests-on-a-margin-that-slipped-lastInveen2026-11-05T23:12:59.730447+00:00LIC's value growth now rests on a margin that slipped last quarterhttps://news.inve.money/uber-s-ride-hailing-growth-slowed-as-drivers-ran-short-and-itInveen2026-11-04T23:42:15.462496+00:00Uber's ride-hailing growth slowed as drivers ran short, and it is shifting incentives to fix ithttps://news.inve.money/amgen-s-newer-drugs-are-growing-faster-than-prolia-and-xgeva-areInveen2026-11-04T23:34:31.205642+00:00Amgen's newer drugs are growing faster than Prolia and Xgeva are shrinkinghttps://news.inve.money/amd-lifts-its-2027-outlook-again-and-the-build-up-behind-itInveen2026-11-04T23:32:06.784335+00:00AMD lifts its 2027 outlook again, and the build-up behind it is already costing cashhttps://news.inve.money/taboola-cuts-its-outlook-saying-readers-now-see-fewer-of-its-adsInveen2026-11-04T23:21:31.301149+00:00Taboola cuts its outlook, saying readers now see fewer of its ads per pagehttps://news.inve.money/in/nykaa-s-profit-jump-came-from-beauty-while-its-fashion-arm-holdsInveen2026-11-04T23:08:40.323989+00:00Nykaa's profit jump came from beauty while its fashion arm holds at breakeven